ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera …
WEBTo fund the acquisition of Alimera, ANI entered into a new senior secured credit agreement consisting of a $325 million delayed draw term loan facility and $75 million revolving credit facility (initial interest rate SOFR+2.75%). ... All forward-looking statements in this news release speak only as of the date of this news release and are based ...
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera …
WEB5 days ago · ANIP. ANI Pharmaceuticals, Inc. PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has ...
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera …
WEB6 days ago · To fund the acquisition of Alimera, ANI entered into a new senior secured credit agreement consisting of a $325 million delayed draw term loan facility and $75 million revolving credit facility ...
ANI Pharmaceuticals Provides Update on Closing of Acquisition of ...
WEBPRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. (“Alimera”) (Nasdaq: ALIM).
News Details - ANI Pharmaceuticals, Inc.
WEBJun 24, 2024 · Further strengthens ANI’s Rare Disease business as the largest driver of future growth: The combination with Alimera will create an attractive Rare Disease growth platform which is expected to account for approximately 45% of pro forma 2024 revenues with robust growth potential.
ANI Pharmaceuticals completes acquisition of Alimera Sciences
WEB4 days ago · ANI noted in a news release that Alimera investors received one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. 1. Nikhil Lalwani, president and CEO of ANI, pointed out that the acquisition marks a major milestone in the ...
ANI Pharmaceuticals and Alimera Sciences Announce Closing …
WEBSep 11, 2024 · PRINCETON, N.J. & ATLANTA-- (BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced...
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
WEBJun 25, 2024 · Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
Alimera Sciences shares jump by 77% after being acquired by ANI
WEBJun 24, 2024 · Alimera’s share price shot up by 77% in premarket trading today, following the announcement of the transaction, valued at $381m. The deal is expected to close in the third quarter (Q3) of 2024.
ANI Pharmaceuticals and Alimera Sciences Announce Closing …
WEBSep. 11, 2024, 06:50 AM. PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera ...